Fig 5.

Treatment response. Positron emission tomography (PET)/computed tomography (CT) scan of giant cell tumor of bone (A) at presentation (ie, baseline) and (B) after 8 weeks of denosumab, which shows minimal decrease in size but significant decrease in fluorodeoxyglucose (FDG) avidity. (C) A deep mesenteric and abdominal desmoid tumor (C) at baseline experienced (D) a dramatic response to sequential sorafenib (5 weeks, discontinued for hypertension) followed by liposomal doxorubicin (two cycles). PET/CT of recurrent pigmented villonodular synovitis (E) at presentation and (F) after 3 months of imatinib that shows significant decrease in tumor size and FDG avidity. Images courtesy of David Thomas, MBBS, PhD, Garvan Institute of Medical Research, Darlinghurst, Australia; Robert Lefkowitz, MD, Department of Radiology, and Marylou Keohan, MD, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; and Vinod Ravi, MD, Department of Medical Oncology, MD Anderson Cancer Center, Houston, TX.